Sign In
Buy MGTA
$0.700
+0 (+0%)
At Close: Dec 08, 2023
Magenta (MGTA) Looks Good: Stock Adds 5.2% in Session
12:40pm, Monday, 06'th Jul 2020
Magenta (MGTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Big DraftKings Investor Bought Up an Embattled Biotech Stock
11:00am, Sunday, 05'th Jul 2020
An Atlas Venture affiliate just paid $10 million for more shares of Magenta Therapeutics. Atlas is also the fourth-largest shareholder in sports-betting company DraftKings.
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the closing
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell
Why Shares of Magenta Therapeutics Are Plunging Today | The Motley Fool
04:51pm, Thursday, 25'th Jun 2020
The company announced the pricing of a public offering of common stock.
Magenta Therapeutics Announces Pricing of Public Offering
12:20am, Thursday, 25'th Jun 2020
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced the pricing
Magenta Therapeutics Announces Pricing of Public Offering
12:00am, Thursday, 25'th Jun 2020
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA | MarketScreener
09:47pm, Wednesday, 24'th Jun 2020SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
09:46pm, Wednesday, 24'th Jun 2020
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
Magenta Therapeutics Launches Proposed Public Offering
08:21pm, Wednesday, 24'th Jun 2020
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has
Magenta Therapeutics Launches Proposed Public Offering
12:00am, Wednesday, 24'th Jun 2020
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
10:54pm, Monday, 22'nd Jun 2020
Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. (“Magenta” or the “Company”) (NASDAQ: MGTA). Such investors are advised to contact Robert S. Willou
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
11:10pm, Saturday, 20'th Jun 2020
NEW YORK, NY / ACCESSWIRE / June 20, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA). Such ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA
04:40pm, Wednesday, 17'th Jun 2020
NEW YORK, NY / ACCESSWIRE / June 17, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Magenta Therapeutics, Inc. ("Magenta" or the "Company") (NASDAQ:MGTA). Such ...
